CytoDyn to present updated Phase 2 CLOVER trial data at ESMO 2026
CYDY•CytoDyn plans to present updated Phase 2 CLOVER trial data on leronlimab combinations for metastatic colorectal cancer on Oct. 25, 2026, in Madrid.
1. Presentation scheduled
CytoDyn flagged updated clinical data from its Phase 2 CLOVER trial for presentation at the ESMO Congress on Oct. 25, 2026, in Madrid. The study evaluates leronlimab alongside established therapies in previously treated patients with metastatic colorectal cancer; results have not yet been presented.
